Guidant pushes ahead with carotid stent trial:
This article was originally published in Clinica
Executive Summary
In a further step in the race to market the first carotid artery stent, Guidant has completed enrolment in a second clinical trial of its Rapid Exchange (RX) Acculink embolic protection device. Called ARCHeR RX (Acculink for revascularisation of carotids in high-risk patients), the trial is a nonrandomised, multicentre study of 145 patients in five different countries. It is designed to show equivalence in safety and performance of the RX enhanced filter design, with Guidant's first generation Acculink and Accunet devices. The announcement comes shortly after Cordis and MedNova released positive clinical trial results of competing products.